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Liver Tumor Development: c-Jun Antagonizes
the Proapoptotic Activity of p53
specific functions of c-Jun for cell survival and cell-
cycle progression imply that this gene might be a major
regulator in the development of hepatic carcinomas.
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Rainer Zenz, Jean-Pierre David, Martina Rath,
and Erwin F. Wagner*
Research Institute of Molecular Pathology (IMP) Human hepatocellular carcinoma (HCC) is the most
frequent form of primary liver cancer. EpidemiologicalDr. Bohrgasse 7
A-1030 Vienna studies have demonstrated that exposure to chemicals
such as aflatoxin B1 and chronic infection with hepatitisAustria
viruses are major risk factors for the development of
HCC (Okuda, 2000). The etiology of HCC has been inves-
tigated in mouse models where liver tumors have beenSummary
induced by carcinogens. The morphological character-
istics of these chemically induced tumors are very simi-The transcription factor c-Jun mediates several cellu-
lar processes, including proliferation and survival, and lar to that of human tumors. Foci of cellular alteration
appear as early lesions and, at later stages, more pro-is upregulated in many carcinomas. Liver-specific in-
activation of c-Jun at different stages of tumor devel- gressed hepatocellular adenomas and carcinomas have
been found, which finally give rise to metastases (Pitot,opment was used to study its role in chemically in-
duced hepatocellular carcinomas (HCCs) in mice. The 1990; Masui et al., 1997). The genetic alterations underly-
ing the development of these neoplastic lesions are notrequirement for c-jun was restricted to early stages
of tumor development, and the number and size of unique for liver tumors but were also identified in tumors
of other tissues. Tumor suppressor genes such as p53hepatic tumors was dramatically reduced when c-jun
was inactivated after the tumor had initiated. The im- (Hsu et al., 1991), retinoblastoma (Murakami et al., 1991),
and -catenin (de La Coste et al., 1998) are frequentlypaired tumor development correlated with increased
levels of p53 and its target gene noxa, resulting in the mutated, and oncogenes that regulate proliferation or
apoptosis of hepatocytes such as Ras and c-Myc areinduction of apoptosis without affecting cell prolifera-
tion. Primary hepatocytes lacking c-Jun showed in- often activated (Zhang et al., 1990). In addition, the sig-
naling pathways for IGF-II (Rogler et al., 1994) and TGF-creased sensitivity to TNF--induced apoptosis, which
was abrogated in the absence of p53. These data indi- (Jhappan et al., 1990) seem to be especially important
in liver cancer, since these growth factors can give risecate that c-Jun prevents apoptosis by antagonizing
p53 activity, illustrating a mechanism that might con- to liver tumors in mice when overexpressed as trans-
genes.tribute to the early stages of human HCC development.
c-Jun is activated in chemically induced murine liver
tumors and in HCCs of humans (Yuen et al., 2001), sug-Introduction
gesting an important oncogenic function for this gene
in liver tumors of mammals. The oncogenicity of c-Jun isThe transcription factor c-Jun has been implicated in
several cellular processes including proliferation, cell probably due to several mechanisms: c-Jun cooperates
with Ras in tumor cell proliferation (Johnson et al., 1996),survival, and cell transformation (Jochum et al., 2001;
Vogt, 2001). Although c-Jun is expressed in a variety of and it can affect the anti-proliferative activity of p53 by
direct repression of p53 transcription (Schreiber et al.,tissues and is a bona fide oncogene for many cell types,
it seems to be especially important for hepatocytes. 1999). In addition, c-Jun modulates TNF- and TGF-
signaling pathways, both of which are implicated in liverThis has been demonstrated in chimeric mice that were
generated with c-Jun-deficient embryonic stem (ES) tumor development (Knight et al., 2000; Kanzler et al.,
2001).cells. ES cell derivatives were found in all organs but
were absent among hepatocytes (Hilberg et al., 1993). The significance of c-Jun as a major regulator of hepa-
tocyte proliferation and apoptosis prompted us to in-Although ES cells were able to differentiate into fetal
hepatocytes, they were progressively lost in the livers of vestigate the function of this gene in liver cancer. The
chimaeric mice after birth, presumably by an apoptotic experimental design is based on liver-specific gene in-
mechanism (Eferl et al., 1999). Interestingly, the precise activation of c-jun and induction of liver tumors by a
function of c-Jun in hepatocytes seems to depend on chemical carcinogenesis protocol in the presence or
their differentiation stage. Fetal hepatocytes require absence of c-Jun. We found that deletion of c-Jun inter-
c-Jun for cell survival since c-Jun knockout mice die at fered dramatically with liver tumor formation. The number
midgestation with increased numbers of apoptotic cells of apoptotic cells was markedly increased in c-Jun-defi-
in the fetal liver (Hilberg et al., 1993; Eferl et al., 1999). cient tumors, and the levels of p53 and its proapoptotic
Differentiated hepatocytes, rather, require c-Jun for cell- target gene noxa were concomitantly upregulated. Analy-
cycle progression since conditional deletion of c-Jun in sis of primary hepatocytes showed that c-Jun can re-
adult livers mainly reduced the proliferation capacity of press the proapoptotic activity of TNF-by antagonizing
hepatocytes after partial hepatectomy, a strong inducer p53, which seems to execute TNF--induced apoptosis
of cell-cycle reentry (Behrens et al., 2002). These liver- in c-Jun-deficient hepatocytes. These data suggest that
c-Jun is an antagonist of p53 in primary hepatocytes
and in liver tumors.*Correspondence: wagner@nt.imp.univie.ac.at
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Figure 2. Experimental Conditions to Define the Role of c-Jun in
Liver Tumors
Development of tumors was initiated at 4 weeks of age (arrow) by
a single injection of Diethylnitrosoamine (DEN), and tumor promotion
was started at 8 weeks with food containing the tumor promoter
Figure 1. Liver-Specific Inactivation of c-jun by the Alfp-cre and Phenobarbital (Pb). c-jun was deleted at different stages of tumor
Mx-cre Transgenes formation with the Alfp-cre (c-junli) or the inducible Mx-cre (c-junli*)
transgenes. The inducible Mx-cre transgene was activated by injec-(A) Southern blot analysis showing the floxed (f) and deleted ()
tion of poly I/C (*). (A) Depicts the experimental design to investigatealleles of c-jun in liver tissue and isolated hepatocytes (hep) of
the function of c-Jun in liver tumor formation, (B) in tumor initiation,c-junli (Alfp-cre, c-junf/f ) and in liver tissue of c-junli* (Mx-cre, c-junf/f )
(C) in tumor promotion, and (D) in tumor progression. (E) A phosphor-mice; c-junf/f mice without a transgene were used as controls. Dele-
ylation-deficient variant of c-Jun, present in JunAA mice, was usedtion of c-jun in liver tissue of c-junli* mice was induced by a single
to study the function of N-terminal Jun phosphorylation in liver tumorinjection of poly I/C. Poly I/C triggers an antiviral response, thereby
development.leading to interferon  production. Interferon  then activates ex-
pression of the Mx-cre transgene. No deletion was induced with
the carcinogen Diethylnitrosamine (DEN).
We next induced liver tumors by a well-established(B) RNase protection assay of AP-1 family members from livers and
chemical carcinogenesis protocol (Kato et al., 1993). Inisolated hepatocytes (hep) of c-junf/f (control) and c-junli mice. The
this protocol, tumors are initiated by the genotoxic drugamount of GAPDH mRNA is shown as a loading control.
diethylnitrosamine (DEN) at 4 weeks of age and pro-
moted by the tumor promoter phenobarbital (Pb) start-
ing at 8 weeks of age (Figure 2A). Liver cell necrosisResults
after administration of DEN was demonstrated by the
increased activities of the markers for liver damage,c-Jun Is Required for Liver Tumor Development
We have chemically induced liver tumors in c-junli mice glutamate-oxalacetate transaminase (GOT), and gluta-
mate-pyruvate transaminase (GPT) in the peripheralto investigate the function of c-Jun in hepatic tumorigen-
esis. The c-junli mice carry conditional floxed alleles of blood. The increase of GOT and GPT activities was not
significantly different in control and c-junli mice, dem-c-jun (c-junf/f) (Behrens et al., 2002) and the Alfp-cre
transgene (Kellendonk et al., 2000). The Alfp-cre trans- onstrating that DEN can induce necrosis in both geno-
types to a similar extent (see Supplemental Figures S1Agene mediates liver-specific deletion of c-jun around
birth (Behrens et al., 2002) with almost 100% efficiency and S1B online at http://www.cell.com/cgi/content/full/
112/2/181/DC1).in purified hepatocytes as demonstrated by Southern
blot analysis (Figure 1A). This result was confirmed by The survival rate of control and c-junli mice was fol-
lowed after tumor induction (Figure 3A). Lethality ofan RNase protection assay, which showed complete
absence of c-jun mRNA in hepatocytes, whereas the c-junf/f mice (controls) started already at 6 months and
increased dramatically at 12 months of age. After 18expression pattern of the other AP-1 family members
was not changed (Figure 1B). In crude liver tissue of months, 60% of control mice but only 10% of c-junli
mice had died. Large tumor nodules were macroscopi-c-junli mice, the nondeleted floxed allele of c-jun was
still detectable, which is due to the lack of deletion cally visible in control mice 6 months after tumor induc-
tion (Figure 3B), and at later stages tumors occupiedin nonparenchymal liver cells (Figure 1A). These data
demonstrate that the Alfp-cre transgene leads to hepa- most of the liver tissue (see Supplemental Figures S2E–
S2G online at http://www.cell.com/cgi/content/full/112/tocyte-specific deletion of c-jun in c-junli mice.
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Figure 3. c-Jun Is Essential for Development
of Liver Tumors
(A) Lethality curves of c-junf/f (control) and
c-junli mice after liver tumor formation.
(B and C) Livers of c-junf/f (control) and c-junli
mice 6 months after tumor initiation/promo-
tion. Some tumors in the control liver are
shown by dotted circles, whereas no tumors
are macroscopically visible in the c-Jun-defi-
cient livers (c-junli) (the asterisk in C indicates
connective tissue).
(D and E) H&E-stained sections of typical eo-
sinophilic liver tumors in c-junf/f (control) and
c-junli mice.
(F and G) Immunohistochemistry of c-Jun in
nontumorigenic liver tissue of c-junf/f (control)
and c-junli mice, respectively. Immunoreac-
tivity of c-Jun is shown in the nuclei of control
livers as brown staining.
(H and I) Immunohistochemistry of c-Jun in




2/181/DC1). The lethality of the control mice was due apoptosis in tumors (Figure 5E). This indicates that the
survival function of c-Jun is required after tumor initia-to primary liver tumors that finally led to liver failure.
Metastases in the lung (see Supplemental Figure S2H), tion. In addition, the survival function is independent
from tumor promotion, since tumorigenesis was im-which are also described for this carcinogenesis model
(Vesselinovitch et al., 1984), were only rarely observed paired and apoptosis was increased in tumors of c-junli*
mice that had only been initiated, but not promotedin these animals and therefore did not contribute to
lethality (data not shown). In contrast, tumor mass was (Figures 5C and 5E; see protocol in Figure 2C).
severely reduced in c-junli mice (Figure 3C). Histologi-
cally, fewer eosinophilic tumors were found, and they Tumor Formation Is Not Impaired in JunAA Mice
were much smaller than those in the control livers (Fig- In order to investigate whether activation of c-Jun by
ures 3D, 3E, and 5A). To exclude the possibility that the N-terminal phosphorylation is required to protect liver
small tumors in c-junli mice are derived from liver cells tumor cells from apoptosis, tumor formation was in-
that had escaped c-jun deletion, the genotypes of c-junli duced in JunAA mice (see protocol in Figure 2E). JunAA
tumors were analyzed by Southern blot (data not mice were generated by a knockin strategy of the JunAA
shown), RNase protection assay (data not shown), and allele into the c-jun locus. The JunAA protein lacks the
immunohistochemistry (Figures 3H and 3I). All tumors major N-terminal phosphorylation sites that are recog-
isolated from c-junli mice were negative for c-jun mRNA nized by Jun-aminoterminal kinases (JNKs) (Behrens et
and protein (Figure 3I), indicating that they are derived al., 1999) and therefore cannot be phosphorylated and
from c-Jun-deficient liver cells. In contrast, control tu- activated by JNKs. We found that tumor formation was
mors were positive for c-Jun protein and expressed not impaired in JunAA mice, and apoptosis was not
c-Jun at higher levels than the surrounding nontumori- increased in JunAA tumors (Figures 5D and 5E), which
genic liver tissue (Figures 3F and 3H). These data dem- indicates that the JunAA allele of c-jun is sufficient to
onstrate that deletion of c-Jun can largely suppress liver protect liver tumor cells from apoptosis.
tumor formation.
Inactivation of c-Jun in Advanced Tumors
c-Jun Protects Liver Tumor Cells from Apoptosis Does Not Impair Tumor Progression
In order to understand the mechanism by which the To investigate whether the survival function of c-Jun is
absence of c-Jun affects tumor formation, we analyzed required for tumor progression, tumors were induced in
the proliferation and apoptosis rates in control and c-junli* mice and were allowed to develop in the pres-
c-junli tumors. The proliferation rate, as ascertained by ence of c-Jun for 6 months (see protocol in Figure 2D).
the counting of mitotic cells on H&E-stained sections After that time, eosinophilic tumors with large tumor
and by immunohistochemical staining of tumor sections cells were most frequently observed. Basophilic tumors,
with the proliferation marker Ki67, was identical in con- mainly described in mouse livers after neonatal injection
trol and c-junli tumors (data not shown and Figures 4A, of DEN (Hacker et al., 1991), were rarely found (see
4B, and 4E). In contrast, the numbers of apoptotic cells Supplemental Figures S2A–S2D). In addition, a small
were 5-fold increased in c-junli tumors as demonstrated percentage of more progressed, large eosinophilic tu-
by a TUNEL assay (Figures 4C, 4D, and 4F). These data mors was identified and characterized as benign adeno-
suggest that c-Jun is required for survival of liver tumor mas by different staining techniques that are derived
cells, which can explain the reduced tumor formation in from hepatocytes (see Supplemental Figures S3A–S3F
c-junli mice. online at http://www.cell.com/cgi/content/full/112/2/
181/DC1). Carcinomas were not readily found at this
time. We induced deletion of c-Jun in these morphologi-c-Jun Is Required for Tumor Cell Survival
after Tumor Initiation cally well-characterized tumors by injection of poly I/C
and analyzed the consequence of deletion on tumorMultistage carcinogenesis can be separated in three
distinct stages: tumor initiation, tumor promotion and progression and apoptosis. We observed a dramatic
increase of tumor volumes between 6 months (time oftumor progression. In order to investigate at which stage
c-Jun is required for survival of liver tumor cells, we c-jun deletion) and 9 months (compare Figures 3B and
6A) after tumor induction in control and c-junli* mice.induced deletion of c-Jun at different times after tumor
initiation (Figures 2B and 2D). This was performed in Highly vascularized tumors were found (Figures 6A and
6B), and histological analysis demonstrated the pres-mice carrying floxed alleles of c-jun and the Mx-cre
transgene (c-junli* mouse model) (Kuhn et al., 1995). The ence of carcinomas, growing in five and more cell layers,
in both genotypes (Figures 6C and 6D). Grading of tumorexpression of the Mx-cre transgene can be induced by
injection of poly I/C, which leads to almost complete dysplasia of 380 tumors, according to the human WHO
grading criteria, demonstrated no major differences ex-deletion of c-jun in crude liver tissue (hepatocytes and
nonparenchymal cells) as demonstrated by Southern cept for a decreased number of tumors in dysplasia
stage G1 in c-junli* mice (Figure 6E). However, the per-blot analysis (Figure 1A) (Kuhn et al., 1995) and by immu-
nohistochemistry (data not shown). centage of tumors in the adenoma and carcinoma
stages was identical in control and c-junli* mice, whichWe induced tumors in c-junli* mice according to the
protocol in Figure 2B (note that c-Jun was deleted after suggests that advanced tumors become independent
of c-Jun, allowing the progression to malignant stagestumor initiation) and compared the efficiency of tumor
formation to that observed in c-junli mice (deletion of also in c-junli* mice. Moreover, deletion of c-jun in ad-
vanced tumors did not result in tumor regression sincec-jun before tumor initiation). In both mouse models,
tumor formation was reduced to a similar degree (Fig- the tumor numbers and the tumor mass were not signifi-
cantly different in control and c-junli* mice (data notures 5A and 5B) and was accompanied by increased
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Figure 4. c-Jun Protects Liver Tumor Cells
from Apoptosis and Does Not Appear to Af-
fect Cell Proliferation
(A and B) Immunostaining of the proliferation
marker Ki67 of c-junf/f (control) tumors and
c-junli tumors 6 months after tumor initiation/
promotion. Arrows indicate Ki67-positive
cells.
(C and D) TUNEL-staining for apoptotic cells
of c-junf/f (control) tumors and c-junli tumors.
Green fluorescence indicates apoptotic cells
(arrows).
(E) Quantification of Ki67-positive cells in
nontumorigenic tissue and tumor tissue of
c-junf/f (control) and c-junli mice. The results
represent mean values of 19 c-junf/f (control)
tumors and 8 c-junli tumors. Note the differ-
ent scales for nontumorigenic tissue and
tumors.
(F) Quantification of TUNEL-positive cells in
nontumorigenic tissue and tumor tissue of
c-junf/f (control) and c-junli mice. The results
represent mean values of 19 c-junf/f (control)
tumors and 13 c-junli tumors.
shown; Figure 6F), and apoptosis was only slightly in- levels of Bcl-2 family members (bcl-w, bfl-1, bcl-x l/s,
bcl-2, bak, bax, bad) and death receptors (TNF-, TRAIL,creased in c-junli* tumors (Figure 6G). These data sug-
gest that c-Jun is required for survival of liver tumor TNR- R p55, TRADD, Rip, caspase 8, FasL, Fas, Faf,
Fap, TGF- 1, TGF- RII, TGF- 3) were analyzed incells between the initiation and progression stages, but
becomes dispensable in more progressed tumors. tumors, nontumorigenic tissues, and isolated hepato-
cytes by RNase protection assay (see Supplemental Fig-
ure S4A online at http://www.cell.com/cgi/content/full/c-Jun Protects Hepatocytes from TNF- Induced
Cell Death by Antagonizing p53 Activity 112/2/181/DC1). The expression levels of these genes
were not significantly different in control and c-junliTo study the molecular mechanism for the increased
apoptosis in c-Jun-deficient liver tumors, the expression tumors, which indicates that c-Jun does not regulate
Cell
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Figure 5. c-Jun Is Required for Survival of
Liver Tumor Cells after Tumor Initiation
Experimental mice were sacrificed and ana-
lyzed 6 months after tumor initiation and pro-
motion. (A) Tumor formation in c-junli mice
where c-jun was deleted throughout tumor
development. (B) Tumor formation in c-junli*
mice where c-jun was deleted after tumor ini-
tiation. (C) Tumor formation in c-junli* mice
without tumor promotion. (D) Tumor forma-
tion in JunAA mice, which are deficient in
N-terminal Jun phosphorylation. Tumor mass
(% of liver tissue), the number of tumors per
cm2 of liver section, and the average area per
tumor are indicated. (E) Numbers of apoptotic
cells per cm2 of tumor area in tumors of mu-
tant and tumors of corresponding control
mice. Apoptosis was quantified in tumors of
c-junli mice (n 184), c-junli* mice (n 220),
c-junli* mice without tumor promotion (n 
37), and JunAA mice (n  342) on H&E-
stained sections according to the following
morphological criteria: fragmentation of nu-
clei, loss of cell-cell interactions between
apoptotic and adjacent cells, and eosino-
philia of apoptotic cells.
the expression of the main modulators of apoptosis in found that the basal activities of stress kinases JNK
and p38 were strongly increased in c-junli hepatocytesthese neoplasias.
The response of c-junli hepatocytes to death ligands (Figure 7C). Although TNF- was able to activate JNK
and p38 in control hepatocytes as well, their activitieswas tested in primary hepatocyte cultures. Activation
of Fas signaling induced apoptosis in control and c-junli never reached the levels in c-junli hepatocytes. Activa-
tion of other kinases such as the ERKs was not substan-hepatocyte cultures with similar efficiency (Figure 7A),
and TGF- failed to induce apoptosis at all, even at high tially changed and phosphorylation of AKT, one of the
major targets of PI3-kinase, was not detectable (Figureconcentrations (20 ng/ml). We therefore conclude that
these death ligands do not contribute to the increased 7C). These data suggest that TNF- can activate NF-B
in c-junli hepatocytes, which transcriptionally inducesapoptosis seen in c-junli tumors. TNF- can induce
apoptosis in hepatocyte cultures only when transcrip- genes that are required for cell survival. However, high
basal activity of JNK might sensitize c-junli hepatocytestion is blocked by D-galactosamine (D-GalN) (Leist et
al., 1994). We observed that TNF- is able to induce to TNF--induced apoptosis.
Stress kinases JNK and p38 have been reported toapoptosis in c-junli hepatocytes without D-GalN pre-
treatment, whereas control hepatocytes were largely activate the tumor suppressor protein p53 (Bulavin et al.,
1999; Buschmann et al., 2001), and data from fibroblastsresistant (Figure 7A). The c-junli hepatocytes detached
from the substratum even at low doses (0.2 ng/ml) of have shown that c-Jun can block p53 transcription
(Schreiber et al., 1999). To test whether p53 activityTNF- and stained positive in the TUNEL reaction (Fig-
ure 7B). This demonstrates that deletion of c-Jun sensi- contributes to TNF--mediated sensitivity of c-junli he-
patocytes, we generated mice deficient for c-Jun andtizes hepatocytes to TNF- induced apoptosis.
Activation of the bcl-2 members A1/bfl-1 and bcl-x L/S p53. Deletion of p53 in the c-jun null background re-
stored resistance of hepatocytes toward TNF- (Figureby the transcription factor NF-B and downregulation of
JNK activity are important events to protect hepatocytes 7D). This indicates that c-Jun protects hepatocytes from
TNF- induced apoptosis by antagonizing activation offrom TNF--induced apoptosis. Expression of the bona
fide NF-B target gene A1/bfl-1 was similarly induced p53. Although p53 appeared to be activated, we were
unable to detect increased p53 mRNA and protein levelsby TNF- in control and c-junli hepatocytes as demon-
strated by RNase protection assay (see Supplemental in c-junli hepatocytes (see Supplemental Figure S4C).
Figure S4B). Bcl-x L/S was not induced by TNF- but
was expressed at similar levels in control and c-junli p53 Protein and Noxa mRNA Are Markedly
Increased in c-junli Tumorshepatocytes (see Supplemental Figure S4B). This is con-
sistent with recent findings that bcl-x L/S is not a direct To test whether stress kinases and p53 contribute to
the increased apoptosis seen in c-junli tumors, stresstarget gene of NF-B (Tang et al., 2001). However, we
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Figure 6. No Inhibition of Liver Tumor Pro-
gression When c-jun Is Inactivated in Ad-
vanced Tumors
Advanced stages of liver tumors like adeno-
mas and carcinomas can form in the absence
of c-Jun. (A and B) Livers of c-junf/f (control)
and c-junli* mice after late deletion of c-jun.
Both livers show highly vascularized large tu-
mors. (C and D) H&E-stained liver sections of
advanced tumor stages in c-junf/f (control)
and c-junli* mice after late deletion of c-jun.
The transformed hepatocytes form more than
three cell layers (arrows), which is character-
istic for carcinomas. (E) Tumor grading of ad-
vanced tumors in c-junf/f (control) and c-junli*
mice after late deletion of c-jun. (F) Quantifi-
cation of liver to body weight ratios of c-junf/f
(control) and c-junli* mice after tumor forma-
tion. Pb, mice that were promoted with Phe-
nobarbital for 6 months; DENPb, mice that
were initiated and promoted for 6 months; 
late, mice that were initiated and promoted
for 6 months. Then c-jun was deleted with
poly I/C, and tumors were allowed to grow
and to progress for an additional 3 months.
(G) Quantification of apoptotic cells ac-
cording to morphological criteria in c-junli*
tumors after late deletion of c-jun (n  700).
kinase activities and p53 expression were analyzed in shown to be a target gene of p53 (Oda et al., 2000) was
selectively induced in c-junli tumors. On the other hand,liver tumor biopsies. Surprisingly, phospho-JNK was un-
detectable, and phospho-p38 levels were unchanged in expression of other p53-dependent proapoptotic genes
such as bax, puma, and apaf-1 was unchanged (Figurec-junli tumors (see Supplemental Figure S4D). However,
levels of p53 protein were strongly increased in c-junli 7F). These data indicate that p53 is most likely responsi-
ble for the increased apoptosis in c-junli tumors bytumors (Figure 7E). The p53 protein was functional and
not inactivated by somatic mutations in the coding re- upregulating the proapoptotic gene noxa.
gion as demonstrated by sequence analysis of p53 in
five control and five c-junli tumors (see Supplemental Discussion
Figure S4E). Semiquantitative RT-PCR analysis was per-
formed to test whether p53 is transcriptionally active in Two conditional mouse models for liver-specific and
tumor-stage-specific inactivation of c-Jun were estab-c-junli tumors. In addition to the p53 gene itself, the
bona fide target gene of p53, mdm2, was upregulated lished to study the molecular mechanisms of c-Jun func-
tions in hepatocarcinogenesis. Tumor formation afterin c-junli tumors (Figure 7F). Most strikingly, the gene
for the BH3-only protein Noxa, which was previously application of a chemical tumor initiation/promotion pro-
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Figure 7. p53-Dependent Apoptosis in Cultured Hepatocytes following TNF- Stimulation and Overexpression of p53 in Liver Tumors of c-junli
Mice
(A) The response to death ligands was assayed with primary hepatocytes of c-junf/f (control) and c-junli mice that were treated with TNF-
(20 ng/ml)  D-GalN (5 mM), TNF- (20 ng/ml), antiFas antibody Jo2 (104), or TGF- (20 ng/ml). The amount of cell death was measured by
release of LDH into the supernatants.
(B) Hepatocyte cultures of c-junf/f (control) and c-junli mice 20 hr after treatment with TNF- (0.2 ng/ml). Arrows indicate detached cells in
the phase-contrast (PC) images and apoptotic cells in the TUNEL-stained images.
(C) Kinase activities were assayed by Western blot in hepatocyte cultures after stimulation with TNF-. Treatment of hepatocytes with UV
(40J/m2) and protein extracts from newborn hearts were used as controls. Abbreviations: p-p38, phospho-p38; p-JNK, phospho-JNK; p-ERK,
phospo-ERK; p-AKT, phosphorylated PI3-kinase substrate AKT. -tubulin was used as a loading control.
(D) Deletion of p53 in c-junli hepatocytes (cells were isolated from c-Jun/p53 double knockout livers) abrogates TNF--sensitivity but does
not protect against FasL-mediated apoptosis. The response to death ligands was assayed with primary hepatocytes of c-junli p53/ mice
(controls) and c-junli p53/ mice that were treated with antiFas antibody Jo2 (104), TNF- (20 ng/ml)  D-GalN (5 mM), and TNF- (20 ng/ml).
(E) Western blot analysis of p53 in liver tumors. p53 levels are strongly upregulated in tumors from c-junli mice. The proteasome component
26S was used as a loading control.
(F) Semiquantitative PCR was performed to analyze the expression of p53 and p53 target genes in tumors and nontumorigenic tissue. PCR
products of undiluted and diluted (1:10) cDNA samples are shown.
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tocol was severely reduced in c-Jun-deficient livers, re- study how c-Jun protects liver tumor cells from apopto-
sis. These tissue culture experiments demonstrated thatsulting in long-term protection toward tumor formation
and reduced mortality. We have recently shown that c-Jun-deficient hepatocytes respond differently to
TNF-, but not to other death ligands such as TGF-c-Jun is required for cell proliferation of adult hepato-
cytes and for liver regeneration after partial hepatec- (Oberhammer et al., 1992) or FasL (Ogasawara et al.,
1993). TNF- is only cytotoxic for hepatocytes whentomy (Behrens et al., 2002). Interestingly, the absence
of c-Jun had no apparent effect on the proliferation rates transcription is blocked by D-galactosamine (Leist et
al., 1994). We found that deletion of c-Jun mimics treat-of liver tumor cells, implying that transformed hepato-
cytes might regulate cell proliferation by mechanisms ment by D-galactosamine and renders hepatocytes sen-
sitive to TNF--induced apoptosis. This suggests thatthat are independent of c-Jun. In contrast, c-Jun is re-
quired for the survival of liver tumor cells. Reduced tu- c-Jun is among the critical transcription factors that
protect hepatocytes from TNF--induced apoptosis.mor formation strictly correlated with high apoptotic
indices in c-Jun-deficient tumors, suggesting that in- Apart from c-Jun, the transcription factor NF-B is re-
quired to protect hepatocytes from TNF--mediatedcreased apoptosis in c-Jun-deficient liver tumors is the
primary cause for impaired tumorigenesis. In analogy apoptosis (Liu et al., 1996). Critical target genes of NF-
B include caspase inhibitors A1/bfl-1 and bcl-x L/Sto liver tumors, c-Jun is required for survival of undiffer-
entiated fetal hepatocytes (Eferl et al., 1999), which indi- (Baldwin, 2001), as well as XIAP and Gadd45, which
antagonize the proapoptotic activity of JNK (Tang et al.,cates that the precise function of c-Jun in cell survival
and cell proliferation might depend on the differentiation 2001; De Smaele et al., 2001). All these genes were
fully activated by TNF- in control and c-Jun-deficientstage of hepatocytes. Murine and human liver tumor
cells resemble fetal hepatocytes since they undergo de- hepatocytes, suggesting that NF-B activation is not
compromised in the absence of c-Jun. Despite XIAPdifferentiation upon neoplastic transformation and start
to reexpress fetal marker genes such as -fetoprotein and Gadd45 expression, basal activities of JNK and
p38 were strongly increased in c-Jun-deficient hepato-(Bellet et al., 1984). In contrast to liver tumors, c-Jun
can act as a proapoptotic factor in other tumor types. cytes, which possibly explains their TNF- sensitivity.
The downstream targets of the stress kinases JNK andThis has been demonstrated for several human cancer
cell lines such as human colorectal carcinoma cells p38 in TNF--induced apoptosis are largely unknown,
but both kinases have been shown to phosphorylate the(Preston et al., 1996) and human leukemia cells (Verheij
et al., 1996). p53 protein (Appella and Anderson, 2001). We showed
that p53 is responsible for TNF- sensitivity of c-Jun-Inducible deletion of c-jun allowed us to define the
tumor stage at which c-Jun functions as a survival factor. deficient hepatocytes, and it is attractive to speculate
that c-Jun antagonizes the proapoptotic activity of p53c-Jun has been implicated in early processes of liver
tumorigenesis such as tumor initiation and tumor pro- by downregulating stress kinase activity.
c-Jun can also antagonize p53 in cell-cycle progres-motion (Pinkus et al., 1993), both of which are linked to
apoptosis (Schulte-Hermann et al., 1992). We demon- sion. We observed that the number of cells in S-phase
was severely reduced in cultures of c-Jun-deficient he-strated that the presence of c-Jun at initiation failed to
restore tumor numbers in c-Jun-deficient livers, which patocytes after EGF/HGF stimulation, and the condi-
tional deletion of c-Jun in the liver of mice impairedindicates that c-Jun is required for liver tumorigenesis
after initiation. We also showed that the increased apo- proliferation of hepatocytes after partial hepatectomy
(Behrens et al., 2002). Deletion of p53 abrogated theptosis in c-Jun-deficient tumors is due to a mechanism
that is independent from tumor promotion, since omit- proliferation defect of c-Jun-deficient hepatocytes in
vitro and rescued liver regeneration after partial hepa-ting the tumor promoter still resulted in increased apo-
ptosis and reduced tumor formation in c-Jun-deficient tectomy in vivo (R.R., unpublished data). Similarly, dele-
tion of p53 abrogated the cell-cycle block of c-Jun-livers. In advanced tumors, deletion of c-Jun did not
substantially increase the apoptotic index nor was tumor deficient 3T3 fibroblasts (Schreiber et al., 1999), which
is caused by increased levels of p53 protein, whereasprogression to malignant stages impaired. This demon-
strates that c-Jun is required for survival of liver tumor p53 levels were not changed in c-Jun-deficient primary
hepatocytes. Recently, it has been demonstrated thatcells at an early stage but becomes dispensable in ad-
vanced tumors by a not yet defined molecular event. c-Jun can regulate p21 protein levels by inhibiting p53
binding to the p21 promoter, a mechanism that couldOne mechanism by which c-Jun can protect liver tu-
mor cells from apoptosis involves Jun activation by account for increased p53 activity in c-Jun-deficient he-
patocytes despite normal p53 protein levels (ShaulianN-terminal phosphorylation. However, analysis of tu-
mors in JunAA mice, which express a phosphorylation- et al., 2000). Taken together, these data demonstrate
that c-Jun can antagonize the proapoptotic and anti-deficient variant of c-Jun, suggests that Jun N-terminal
phosphorylation is not required to protect liver tumor proliferative activities of p53 since most of the pheno-
types caused by deletion of c-Jun are abrogated bycells from apoptosis. As a consequence, liver tumor
formation was not impaired in JunAA mice, whereas the additional deletion of p53. However, the molecular
mechanism how c-Jun antagonizes p53 activity seemsformation of skin and bone tumors, induced by the SOS
and Fos transgenes, was reduced in JunAA mice (Beh- to depend on the particular cell type.
Unlike primary hepatocytes, stress kinase activitiesrens et al., 2000). It is likely that phosphorylated c-Jun
regulates a specific set of target genes that is required were not induced in c-Jun-deficient liver tumors, but p53
mRNA and protein levels were increased. We speculatefor transformed keratinocytes and osteoblasts, but not
for the survival of liver tumor cells. that c-Jun can directly repress transcription of p53 in
liver tumor cells by a mechanism that was recently de-We have employed primary hepatocyte cultures to
Cell
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1993). Despite high levels of c-Jun protein in liver tumors
that may antagonize the proapoptotic activity of p53
throughout tumorigenesis, somatic mutations frequently
inactivate p53 during late-stage tumorigenesis (Bressac
et al., 1991; Hsu et al., 1991). It is likely that in addition
to its proapoptotic activity, other tumor-suppressive ac-
tivities of p53 have to be inactivated to allow further
progression of liver tumors. This would concomitantly
abrogate the requirement for c-Jun to block the proapo-
ptotic activity of p53 and might explain why c-Jun is not
required for tumor progression. It further implies that
Figure 8. Schematic Model Depicting the Survival Function of c-Jun the design of c-Jun inhibitors might prove to be success-in Nontransformed and Transformed Hepatocytes
ful in cancer therapy for tumors at early stages or in
c-Jun antagonizes p53 activity by two different mechanisms: in
cancers that have not yet lost p53 activity.nontransformed hepatocytes, c-Jun regulates p53 posttranscrip-
tionally and we speculate, that the high activities of the stress ki-
nases p38 and JNK in c-junli hepatocytes either directly activate Experimental Procedures
p53 or may contribute indirectly to the p53-mediated cell cycle block
and TNF- sensitivity. Following hepatocyte transformation, c-Jun Animals
regulates p53 at the transcriptional and posttranscriptional level, Mice carrying a floxed c-jun allele (c-junf ) (Behrens et al., 2002) were
thereby preventing p53 upregulation and apoptosis triggered by the crossed either to Alfp-cre (Kellendonk et al., 2000) or Mx-cre mice
p53 target gene noxa. Whether TNF- contributes to p53-mediated (Kuhn et al., 1995). To delete c-jun in the adult liver, Mx-cre c-junf/f
apoptosis of transformed c-junli hepatocytes has to be investi- mice were injected intraperitoneally with 13 mg/kg poly I/C. The
gated. function of c-Jun phosphorylation was studied with JunAA mice,
where the N-terminal serines 63 and 73 have been replaced by
alanines (Behrens et al., 1999). The genetic background was
C57Bl/6 	 129 for Mx-cre c-junf/f and JunAA mice and C57Bl/6 	scribed for c-Jun-deficient 3T3 fibroblasts (Schreiber et
129 	 FVB/N for Alfp-cre c-junf/f mice. Mutant mice were inter-
al., 1999). The extent of posttranscriptional mechanisms crossed at least five times before tumor induction experiments and
being involved in the accumulation of p53 protein in to avoid sex-specific differences in tumor formation, only male mice
were used.c-Jun-deficient liver tumors has yet to be defined. It is
possible that the negative feedback inhibition of p53 by
binding to MDM2 (Alarcon-Vargas and Ronai, 2002) is Chemical Carcinogenesis Protocol
The carcinogen diethylnitrosamine (Sigma) was diluted to 100 mg/mldisrupted since p53 protein accumulated despite in-
with 0.9% NaCl. A single dose of 100 mg/kg body weight was in-creased mdm2 expression.
jected intraperitoneally at 4 weeks of age to initiate tumor formation.The high levels of p53 protein in c-Jun-deficient liver
Tumors were promoted with a diet (Sniff) containing 0.07% pheno-
tumors were associated with increased apoptosis, but barbital (Sigma) until mice were sacrificed.
not with decreased proliferation. A similar finding was
made in chemically induced liver tumors of p53-trans-
Histology, Immunohistochemistry, and TUNEL Assay
genic mice (Gillet et al., 2000). It is possible that high p53 For histological analysis and immunohistochemistry, livers were
expression in liver tumors mainly induces proapoptotic fixed with neutral buffered 4% PFA at 4
C. The tissues were then
genes, but not anti-proliferative genes such as p21. In embedded in paraffin. 5 m sections were stained either with hema-
toxylin and eosin or processed further. Immunohistochemistry stain-support of this hypothesis, expression of the cell-cycle
ing for Ki67 (Novocastra) or c-Jun (Transduction Laboratories) wasinhibitor p21 was not increased in c-Jun-deficient liver
performed using the ABC staining kit (Vector Laboratories) ac-tumors, whereas the proapoptotic p53-target gene noxa
cording to the manufacturers recommendations. TUNEL staining
(Oda et al., 2000) was induced. The expression of other was performed using the in situ cell death detection kit (Roche).
proapoptotic p53 targets like bax, puma, and apaf-1 Nuclei of cells were counterstained with the DAPI reagent.
was unchanged. The noxa gene was recently identified
in a screen for p53 target genes and codes for a proapo- Quantification of Tumors
ptotic member of the BH3-only family of proteins. In- Tumors were identified and counted on H&E-stained liver sections.
triguingly, ectopic expression of noxa in Hela cells The area of liver transections and the area of tumors were quantified
using MetaMorph software. For each liver two transections, whichcaused apoptosis in90% of cells and was also proapo-
were at least 200 m apart, were analyzed.ptotic in other human cancer cell lines (Oda et al., 2000).
These findings suggest that c-Jun prevents apoptosis in
Cell Cultureliver tumors by antagonizing p53 and thereby preventing
Hepatocytes were isolated using the two step collagenase perfusionp53-dependent induction of the proapoptotic noxa
method (Seglen, 1976). The viability of the hepatocytes exceededgene.
70% in all experiments as determined by Trypan-blue exclusion.
In summary, one major function of c-Jun in cell-cycle Cells were plated at 3 	 105 or 2 	 106 hepatocytes per 6-well or
progression and liver tumorigenesis is to antagonize the 10 cm petri dish, respectively. Collagen I-coated dishes (Falcon
Biocoat) were used for all experiments. The cells were allowed toactivity of p53 (Figure 8). In nontransformed hepato-
adhere to culture plates for 3 hr in DMEM containing 15% FCScytes, c-Jun might antagonize p53 activity without af-
(Gibco), 1	 Penicillin/Streptomycin, insulin (105 M), dexametha-fecting p53 mRNA and protein levels. In tumors, c-Jun
sone (107 M), and L-ornithine (0.4 mM). Then the medium wasprevents p53 upregulation and induction of apoptosis.
replaced by serum-free medium containing anti-Fas antibody Jo2
This might also occur in human HCCs that are associ- (Research Diagnostics), TNF- (Sigma), or TGF- (Sigma) at different
ated with hepatitis B virus (HBV) infections, where c-Jun concentrations. Pretreatment with 5 mM D-galactosamine was
started 30 min before addition of TNF-.is activated by the HBx protein of HBV (Kekule et al.,
Role of c-Jun in Liver Cancer
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Apoptosis Assays phosphorylation of c-Jun regulates stress-induced apoptosis and
cellular proliferation. Nat. Genet. 21, 326–329.Release of lactate dehydrogenase (LDH) was determined in the
supernatant of hepatocyte cultures using the CytoTox 96 kit (Pro- Behrens, A., Jochum, W., Sibilia, M., and Wagner, E.F. (2000). Onco-
mega) according to the manufacturers recommendations. Untreated genic transformation by ras and fos is mediated by c-Jun N-terminal
cultures were used as a reference to normalize the results. phosphorylation. Oncogene 19, 2657–2663.
Behrens, A., Sibilia, M., David, J.P., Mohle-Steinlein, U., Tronche, F.,
RNase Protection Assay (RPA) Schutz, G., and Wagner, E.F. (2002). Impaired postnatal hepatocyte
Total RNA was isolated with the TRIZOL protocol (Sigma) and 10 proliferation and liver regeneration in mice lacking c-jun in the liver.
g were used for each RPA reaction. RPA was performed using the EMBO J. 21, 1782–1790.
RiboQuant multi-probe RNase protection assay systems mApo-2,
Bellet, D.H., Wands, J.R., Isselbacher, K.J., and Bohuon, C. (1984).mApo-3, mJun/Fos, and a custom template set (PharMingen) ac-
Serum alpha-fetoprotein levels in human disease: perspective fromcording to the manufacturer’s protocol.
a highly specific monoclonal radioimmunoassay. Proc. Natl. Acad.
Sci. USA 81, 3869–3873.
Sequence Analysis
Bressac, B., Kew, M., Wands, J., and Ozturk, M. (1991). SelectivecDNA samples from liver tumors were amplified with the following
G to T mutations of p53 gene in hepatocellular carcinoma fromprimers for sequencing of p53: p53 (11): cacgtgctcaccctggctaaagtt
southern Africa. Nature 350, 429–431.and p53 (1347): aaggagagggggaggctggtga. The PCR products com-
prised the whole CDS of p53 and were either sequenced directly or Bulavin, D.V., Saito, S., Hollander, M.C., Sakaguchi, K., Anderson,
cloned into a TA vector for sequencing. C.W., Appella, E., and Fornace, A.J., Jr. (1999). Phosphorylation of
human p53 by p38 kinase coordinates N-terminal phosphorylation
and apoptosis in response to UV radiation. EMBO J. 18, 6845–6854.Semiquantitative PCR Analysis
Semiquantitative PCR was performed with different dilutions of Buschmann, T., Potapova, O., Bar-Shira, A., Ivanov, V.N., Fuchs,
cDNA samples from tumor biopsies. The following primers were S.Y., Henderson, S., Fried, V.A., Minamoto, T., Alarcon-Vargas, D.,
used for semiquantitative PCR analysis: c-jun 1, ctcataccagttcgca Pincus, M.R., et al. (2001). Jun NH2-terminal kinase phosphorylation
caggcggc; c-jun 2, ccgctagcactcacgttggtaggc; p53 (1266), aaccgc of p53 on Thr-81 is important for p53 stabilization and transcriptional
cgacctatccttaccatc; p53 (1674), aggccccactttcttgaccattgt; mdm2 activities in response to stress. Mol. Cell. Biol. 21, 2743–2754.
(1324), ttcggccttctcctcgctgtcgtc; mdm2 (873), tggcgtaagtgagcattct de La Coste, A., Romagnolo, B., Billuart, P., Renard, C.A., Buendia,
ggtga; p21 (166), acccgggtccttcttgtgtttc; p21 (589), cgttttcggccctga M.A., Soubrane, O., Fabre, M., Chelly, J., Beldjord, C., Kahn, A., and
gatgttc; noxa (331), gatgaggagcccaagcccaacc; noxa (829), cccaaa Perret, C. (1998). Somatic mutations of the beta-catenin gene are
cgactgcccccatacaa; bax (142), gagcagccgccccaggatg; bax (538), frequent in mouse and human hepatocellular carcinomas. Proc. Natl.
ggtgagcgaggcggtgaggac; puma (323), ccgcctgatgccctccgctgtat; Acad. Sci. USA 95, 8847–8851.
puma (621), cgggcccactcctcctcctccac; apaf-1 (3174), ggtggccgact
De Smaele, E., Zazzeroni, F., Papa, S., Nguyen, D.U., Jin, R., Jones,gcagaggacattt; apaf-1 (3533), gcccaaccccagaactgaagactc;-tubulin1,
J., Cong, R., and Franzoso, G. (2001). Induction of gadd45beta bygacagaggcaaactgagcacc; -tubulin2, caacgtcaagacggccgtgtg.
NF-kappaB downregulates pro-apoptotic JNK signalling. Nature
414, 308–313.Southern and Western Blot Analysis
Eferl, R., Sibilia, M., Hilberg, F., Fuchsbichler, A., Kufferath, I., Guertl,For Southern blots, 10 g of genomic DNA was digested with XbaI
B., Zenz, R., Wagner, E.F., and Zatloukal, K. (1999). Functions ofyielding a 6.9 kb fragment for the floxed c-jun allele and a 3.3 kb
c-Jun in liver and heart development. J. Cell Biol. 145, 1049–1061.fragment for the deleted c-jun allele. For detection of the bands, a
0.6 kb BamHI fragment from the c-jun promoter region was used as Gillet, R., Grimber, G., Bennoun, M., Caron de Fromentel, C., Briand,
a probe. Western blot analysis was performed according to standard P., and Joulin, V. (2000). The consequence of p53 overexpression
procedures using antibodies specific for p53, p38, phospho-p38, for liver tumor development and the response of transformed murine
phospho-JNK, AKT, phospho-AKT, phospho-ERK (all from Cell sig- hepatocytes to genotoxic agents. Oncogene 19, 3498–3507.
naling), and -tubulin (Sigma), 26S prot (gift from J. M. Peters) (Beh- Hacker, H.J., Mtiro, H., Bannasch, P., and Vesselinovitch, S.D.
rens et al., 1999). (1991). Histochemical profile of mouse hepatocellular adenomas
and carcinomas induced by a single dose of diethylnitrosamine.
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